Tylenol maker Kenvue ousts CEO amid board's strategic review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Should l Buy KVUE?
Source: Reuters
Executive Changes at Kenvue: Kenvue has fired CEO Thibaut Mongon amid investor pressure for improved performance, appointing Kirk Perry as interim CEO while also considering portfolio simplification and potential divestitures.
Financial Outlook and Strategic Review: The company is reviewing its operations with the help of advisors to evaluate possible sales of underperforming brands, particularly in its skin-health and beauty unit, and anticipates second-quarter profits aligning with analyst estimates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 17.720
Low
17.00
Averages
18.86
High
23.00
Current: 17.720
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Earnings Release Date: Kenvue (KVUE) is set to announce its Q1 earnings on May 7 before market open, with a consensus EPS estimate of $0.26, reflecting an 8.3% year-over-year growth, indicating sustained profitability.
- Revenue Expectations: The anticipated revenue for Kenvue in Q1 is $3.85 billion, representing a 2.9% year-over-year increase, which illustrates the company's stable performance in the market despite a slight slowdown in growth.
- Historical Performance Review: Over the past two years, Kenvue has beaten EPS estimates 100% of the time and exceeded revenue estimates 63% of the time, showcasing the company's strong financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, Kenvue's EPS estimates have seen three upward revisions and two downward adjustments, while revenue estimates experienced three upward revisions and one downward, indicating some divergence in analysts' outlook on the company's future performance.
See More
- Earnings Beat: Kenvue reported a Q1 Non-GAAP EPS of $0.32, exceeding expectations by $0.06, which reflects the company's robust profitability and enhances market confidence in its financial health.
- Revenue Growth: The company achieved revenues of $3.91 billion, a 4.5% year-over-year increase, surpassing market expectations by $60 million, indicating strong sales momentum in a competitive consumer goods market.
- Margin Improvement: Adjusted operating income margin rose to 24.0% from 19.8% in the prior year, showcasing successful strategies in cost control and operational efficiency, which further boosts investor confidence.
- Currency Benefit: Organic sales growth was 0.7%, while foreign currency benefits contributed 3.8%, demonstrating the positive impact of global market fluctuations on the company's performance; however, no forward guidance was provided due to the pending transaction with Kimberly-Clark.
See More
- Hershey's Recovery: Hershey (HSY) has shown a strong recovery with Q1 2026 net revenue reaching $3.10 billion, a 10.6% year-over-year increase, and gross margin expanding from 33.7% to 39.4%, indicating robust earnings recovery potential after a painful cost crunch.
- General Mills Transformation: General Mills (GIS) is undergoing a transformation post-yogurt divestiture, focusing on its pet food segment, and despite facing organic sales declines, its dividend yield has risen to approximately 7%, providing a stable income opportunity for investors.
- Kimberly-Clark's Kenvue Acquisition: Kimberly-Clark (KMB) is acquiring Kenvue for $48.7 billion, expected to close in H2 2026, which will create a global personal care and health platform with enhanced pricing power across well-known brands, marking a significant strategic shift.
- Consistent Dividend Growth: Kimberly-Clark raised its quarterly dividend to $1.28 per share in January 2026, marking 54 consecutive years of increases, demonstrating its commitment to shareholder returns even amid significant corporate transformation.
See More
- Hershey's Earnings Recovery: With cocoa prices plummeting 74% from their December 2024 peak, Hershey reported Q1 2026 net revenue of $3.10 billion, a 10.6% year-over-year increase, and gross margins expanded from 33.7% to 39.4%, indicating significant profitability improvement, with further enhancements expected in Q2.
- General Mills' Transformation Opportunity: Despite challenges from declining organic sales and rising costs, General Mills' dividend yield has risen to approximately 7%, and its pet food segment remains a stable growth engine within a mature product mix, with management reaffirming its commitment to a $0.61 per share quarterly dividend.
- Kimberly-Clark's Strategic Acquisition: Kimberly-Clark's $48.7 billion acquisition of Kenvue, expected to close in the second half of 2026, will consolidate brands like Kleenex and Huggies under one umbrella, marking a shift from a traditional tissue and diaper company to a global personal care and health brand platform.
- Stability in Consumer Goods Sector: These three companies continue to pay dividends amid market fluctuations, showcasing the long-term value of the consumer goods sector as wealth builders, particularly as investor demand for stable dividend yields increases in the face of economic uncertainty.
See More
- Strong Performance: Kenvue's Q1 revenue and profit surpassed Wall Street expectations, driven by robust sales in its skin health and beauty brands, indicating sustained consumer demand and market potential for health products.
- Acquisition Progress: The consumer health company is in the midst of a $40 billion buyout led by Kimberly-Clark, with the deal expected to close in the second half of the year, which will further enhance Kenvue's market position and resource integration capabilities.
- Brand Strength: Kenvue's skin health and beauty brands showed exceptional sales performance, driving overall growth and demonstrating the company's strong brand influence and consumer loyalty in a competitive market.
- Optimistic Market Outlook: With the acquisition progressing and brand sales increasing, Kenvue is expected to continue benefiting from rising demand for health products, further solidifying its leadership position in the consumer health sector.
See More
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More









